Panelists: Wayne Doyle, PhD Head of Scientific Platforms & StrategyEclipsebio Panelist Wayne Doyle, PhD Wayne...
Upcoming
The U.S. Food and Drug Administration’s approvals of Enhertu for various metastatic breast cancers last...
In today’s competitive biologics and gene therapy landscape, CDMO quality control teams are under pressure...
Clinical trials generate terabytes of imaging data—details on disease status, treatment effects, and progression—but biopharma...
Whole-exome sequencing (WES) is widely used in both clinical and research settings, but current implementations...
With countless nanoparticle formulation options to explore, researchers need a way to quickly identify scalable...
Synthetic biology has long relied on cell-based cloning to address the shortcomings of synthetic DNA....
Target deconvolution, particularly when paired with proteomics techniques, plays a crucial role in drug screening,...
Panelists: Nathaniel Clark, PhD Senior ScientistRepligen Panelist Nathaniel Clark, PhD Nathaniel Clark, PhD, is a...
Bringing a new therapy to market takes years and costs billions, leaving biopharma under increasing...